Bioluminescent Study of the Distribution of High-Molecular-Weight Protein Fraction of Cellex Daily Preparation in the Brain after Intranasal Administation


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Permeability of the blood—brain barrier for protein fractions 50-100 kDa (PF50–100) of Cellex Daily preparation labeled with fluorescent tracer FITC and non-conjugated FITC were compared after intranasal administration of the preparations to healthy rats. Fluorimetrical analysis of the serum and cerebrospinal fluid samples showed that Cellex Daily PF50–100-FITC administered intranasally penetrated into the blood and cerebrospinal fluid with maximum accumulation in 2 h after administration and persists in the circulation for 24 h probably due to binding with plasma proteins. The differences in the kinetic profile of PF50–100-FITC and free FITC indirectly suggest that the major part of the preparation is not degraded within 24 h and FITC is probably not cleaved from the protein components of the preparation. In vivo fluorescence analysis showed significant fluorescent signal in the olfactory bulbs in 6 h after intranasal administration; hence, the preparation administered via this route can bypass the blood—brain barrier. Scanning laser confocal microscopy of rat brain sections confirmed penetration of the high-molecular weight protein fraction PF50–100-FITC into CNS structures. The most pronounced accumulation of the labeled drug was observed in the olfactory bulb in 6 and 12 h after administration. In contrast to free FITC administered in the control group, significant accumulation of PF50–100-FITC in the olfactory cortex and frontal cortex neurons with functionally active nuclei was observed in 6, 12 and 24 h after intranasal administration.

Sobre autores

V. Baklaushev

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency

Autor responsável pela correspondência
Email: serpoff@gmail.com
Rússia, Moscow

G. Yusubalieva

V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Rússia, Moscow

M. Burenkov

Farm-Sintez Company

Email: serpoff@gmail.com
Rússia, Moscow

P. Mel’nikov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency; V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Rússia, Moscow; Moscow

E. Bozhko

Farm-Sintez Company

Email: serpoff@gmail.com
Rússia, Moscow

G. Mentyukov

Farm-Sintez Company

Email: serpoff@gmail.com
Rússia, Moscow

L. Lavrent’eva

Farm-Sintez Company

Email: serpoff@gmail.com
Rússia, Moscow

M. Sokolov

Farm-Sintez Company

Email: serpoff@gmail.com
Rússia, Moscow

V. Chekhonin

V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Rússia, Moscow; Moscow


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies